Work

Preclinical and phase 1 clinical profile of SBP-9330 in development as an aid to smoking cessation

Year: 2024

Type: article

Source: Neuroscience Applied

DOI: 10.1016/j.nsa.2024.104106

Authors: R. Gadient, V. Hingorani, M. Sergeeva, J. Djan, X. Li, B.S. Mckenna, D.J. Sheffler, R. Cosford, A. Birchler, W.J. Breslin, M. DeVries, N.D.P. Cosford, R.M. Anthenelli, G. Velicelebi

Institutions: University of California San Diego, Sanford Burnham Prebys Medical Discovery Institute

Language: English

Topic: Smoking Behavior and Cessation

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000

Funder: National Institute on Drug Abuse

Awards: Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction, G829586

OpenAlex ID: W4405637413

FWCI:

Cites:

Cited by:

Related to: 10